INHIBRX BIOSCIENCES, INC. Shareholders' Equity
INHIBRX BIOSCIENCES, INC. (INBX) had Shareholders' Equity of -$52.98 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent -$52.98M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$21.04M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $7.99M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $36.83M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | -$52.98M 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$21.04M 10-Q · filed 2026-08-13 |
| 2025-12-31 | $7.99M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $36.83M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $68.56M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $94.44M 10-Q · filed 2026-08-13 |
| 2024-12-31 | $133.58M 10-Q · filed 2026-08-13 |
| 2024-09-30 | $178.47M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $219.37M 10-Q · filed 2025-11-14 |
| 2024-03-31 | $11.57M 10-Q · filed 2025-11-14 |
| 2023-12-31 | $43.50M 10-K · filed 2026-03-19 |
| 2023-09-30 | $129.59M 10-Q · filed 2024-11-14 |
| 2023-06-30 | -$24.81M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $15.13M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $58.06M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |